Outlook Therapeutics (FRA:41O) YoY EBITDA Growth : -145.27% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Outlook Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was -145.27%.

Outlook Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-1.22.

Outlook Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for Outlook Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics YoY EBITDA Growth Chart

Outlook Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

YoY EBITDA Growth

Get a 7-Day Free Trial

66.62

72.70

31.70

-5.95

29.89

Outlook Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															68.20	10.51	14.47	44.20	-145.27

Outlook Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Outlook Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Sep. 2023 is calculated as:

	YoY EBITDA Growth (A: Sep. 2023 )
=	(EBITDA per Share (A: Sep. 2023 )	-	EBITDA per Share (A: Sep. 2022 ))	/	\| EBITDA per Share (A: Sep. 2022 ) \|
=	(-4.298	-	-6.13)	/	\| -6.13 \|
=	29.89 %

Outlook Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(-1.219	-	-0.497)	/	\| -0.497 \|
=	-145.27 %

Outlook Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics (FRA:41O) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

OTLK:USA 41ON:Germany

Address

485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics (FRA:41O) Headlines

No Headlines